FRESENIUS SE &/S (OTCMKTS: FSNUY) is one of 113 public companies in the “Surgical & medical instruments” industry, but how does it compare to its peers? We will compare FRESENIUS SE &/S to related companies based on the strength of its analyst recommendations, profitability, institutional ownership, dividends, earnings, risk and valuation.

Valuation and Earnings

This table compares FRESENIUS SE &/S and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
FRESENIUS SE &/S $38.28 billion $2.05 billion 19.17
FRESENIUS SE &/S Competitors $1.44 billion $104.34 million -175.43

FRESENIUS SE &/S has higher revenue and earnings than its peers. FRESENIUS SE &/S is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

0.1% of FRESENIUS SE &/S shares are owned by institutional investors. Comparatively, 49.0% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.8% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for FRESENIUS SE &/S and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FRESENIUS SE &/S 1 0 0 0 1.00
FRESENIUS SE &/S Competitors 642 2362 4484 212 2.55

As a group, “Surgical & medical instruments” companies have a potential upside of 369.26%. Given FRESENIUS SE &/S’s peers stronger consensus rating and higher probable upside, analysts plainly believe FRESENIUS SE &/S has less favorable growth aspects than its peers.

Risk & Volatility

FRESENIUS SE &/S has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, FRESENIUS SE &/S’s peers have a beta of 0.81, indicating that their average share price is 19% less volatile than the S&P 500.

Profitability

This table compares FRESENIUS SE &/S and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
FRESENIUS SE &/S 5.37% 8.76% 3.52%
FRESENIUS SE &/S Competitors -38.83% -90.96% -18.39%

Dividends

FRESENIUS SE &/S pays an annual dividend of $0.15 per share and has a dividend yield of 0.9%. FRESENIUS SE &/S pays out 16.3% of its earnings in the form of a dividend. As a group, “Surgical & medical instruments” companies pay a dividend yield of 1.2% and pay out 32.0% of their earnings in the form of a dividend.

Summary

FRESENIUS SE &/S beats its peers on 8 of the 15 factors compared.

FRESENIUS SE &/S Company Profile

Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis- related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products used in the collection and processing of blood components, as well as in transfusion medicine. The Fresenius Helios segment operates 111 hospitals with approximately 35,000 beds, such as 88 acute care hospitals and 23 post-acute care clinics; 4 post-acute care centers; 17 prevention centers; and 12 nursing homes. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Receive News & Ratings for FRESENIUS SE &/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FRESENIUS SE &/S and related companies with MarketBeat.com's FREE daily email newsletter.